Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)

Kyung Im Kim, Jae Hyun Kim, Eun Hee Ji, Jun Ho Jang, Jinseok Kim, Ji Hyun Kwon, Inho Kim, Seonyang Park, Galina Velikova, Sung Soo Yoon, Jung Mi Oh

Research output: Contribution to journalArticle

Abstract

Purpose: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. Methods: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Results: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach’s α, except for the scales body image and the inpatient issues. Cronbach’s α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. Conclusions: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.

Original languageEnglish
Pages (from-to)881-890
Number of pages10
JournalQuality of Life Research
Volume25
Issue number4
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

Hematopoietic Stem Cell Transplantation
Psychometrics
Quality of Life
Organizations
Drug Therapy
Research
Body Image
Neoplasms
Therapeutics
Bone Neoplasms
Graft vs Host Disease
Bone Marrow Transplantation
Reproducibility of Results
Multicenter Studies
Longitudinal Studies
Inpatients
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Kim, Kyung Im ; Kim, Jae Hyun ; Ji, Eun Hee ; Jang, Jun Ho ; Kim, Jinseok ; Kwon, Ji Hyun ; Kim, Inho ; Park, Seonyang ; Velikova, Galina ; Yoon, Sung Soo ; Oh, Jung Mi. / Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29). In: Quality of Life Research. 2016 ; Vol. 25, No. 4. pp. 881-890.
@article{ed4fc6614dbd40cda41cb331ef5b8ebe,
title = "Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)",
abstract = "Purpose: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. Methods: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Results: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach’s α, except for the scales body image and the inpatient issues. Cronbach’s α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. Conclusions: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.",
author = "Kim, {Kyung Im} and Kim, {Jae Hyun} and Ji, {Eun Hee} and Jang, {Jun Ho} and Jinseok Kim and Kwon, {Ji Hyun} and Inho Kim and Seonyang Park and Galina Velikova and Yoon, {Sung Soo} and Oh, {Jung Mi}",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s11136-015-1121-5",
language = "English",
volume = "25",
pages = "881--890",
journal = "Quality of Life Research",
issn = "0962-9343",
publisher = "Springer Netherlands",
number = "4",

}

Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29). / Kim, Kyung Im; Kim, Jae Hyun; Ji, Eun Hee; Jang, Jun Ho; Kim, Jinseok; Kwon, Ji Hyun; Kim, Inho; Park, Seonyang; Velikova, Galina; Yoon, Sung Soo; Oh, Jung Mi.

In: Quality of Life Research, Vol. 25, No. 4, 01.04.2016, p. 881-890.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29)

AU - Kim, Kyung Im

AU - Kim, Jae Hyun

AU - Ji, Eun Hee

AU - Jang, Jun Ho

AU - Kim, Jinseok

AU - Kwon, Ji Hyun

AU - Kim, Inho

AU - Park, Seonyang

AU - Velikova, Galina

AU - Yoon, Sung Soo

AU - Oh, Jung Mi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. Methods: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Results: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach’s α, except for the scales body image and the inpatient issues. Cronbach’s α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. Conclusions: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.

AB - Purpose: We evaluated the psychometric properties of the Korean version of the European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29) when implemented with Korean patients by conducting a multicenter, longitudinal study in three Korean hospitals. Methods: A total of 226 patients who scheduled to receive the HDC followed by hematopoietic stem cell transplantation (HSCT) were enrolled. The patients were asked to complete three questionnaires [the EORTC Core Questionnaire (QLQ-C30), QLQ-HDC29, and the Functional Assessment of Cancer Therapy-Bone Marrow Transplantation] at four points in time: before HSCT and 100, 180, and 365 days after HSCT. Standard validity and reliability analyses were performed. Results: Internal consistency of the QLQ-HDC29 was generally acceptable, as tested by Cronbach’s α, except for the scales body image and the inpatient issues. Cronbach’s α values for the Korean version of the QLQ-HDC29 were almost in accordance with results of the original version, except for the scales body image (lower to the original QLQ-HDC29, α = 0.73) and impact on family (higher to the original QLQ-HDC29, α = 0.52). Known-group comparison analyses showed significantly higher symptom burdens in patients with poor performance status or graft versus host disease (similar to the original QLQ-HDC29). The QLQ-HDC29 indicated good convergent and discriminant validity and showed responsiveness to changes in line with a clinical course over time after HSCT. Conclusions: The QLQ-HDC29 is generally reliable and adequate to assess QoL in Korean patients undergoing HDC followed by HSCT.

UR - http://www.scopus.com/inward/record.url?scp=84940845614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940845614&partnerID=8YFLogxK

U2 - 10.1007/s11136-015-1121-5

DO - 10.1007/s11136-015-1121-5

M3 - Article

VL - 25

SP - 881

EP - 890

JO - Quality of Life Research

JF - Quality of Life Research

SN - 0962-9343

IS - 4

ER -